{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T01:51:55Z","timestamp":1776477115332,"version":"3.51.2"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s12325-014-0168-y","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T10:24:53Z","timestamp":1417429493000},"page":"1213-1227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Randomized Trial of Brinzolamide\/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular Hypertension"],"prefix":"10.1007","volume":"31","author":[{"given":"Stefano A.","family":"Gandolfi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Cristina","family":"Sanseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Camilo","family":"Parra Restrepo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hamacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,28]]},"reference":[{"key":"168_CR1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/bjophthalmol-2011-300539","volume":"96","author":"D Pascolini","year":"2012","unstructured":"Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012;96:614\u20138.","journal-title":"Br J Ophthalmol"},{"key":"168_CR2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.preteyeres.2012.07.001","volume":"31","author":"DJ Calkins","year":"2012","unstructured":"Calkins DJ. Critical pathogenic events underlying progression of neurodegeneration in glaucoma. Prog Retin Eye Res. 2012;31:702\u201319.","journal-title":"Prog Retin Eye Res."},{"key":"168_CR3","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1167\/iovs.12-9483i","volume":"53","author":"DJ Calkins","year":"2012","unstructured":"Calkins DJ, Horner PJ. The cell and molecular biology of glaucoma: axonopathy and the brain. Invest Ophthalmol Vis Sci. 2012;53:2482\u20134.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"168_CR4","volume-title":"Terminology and Guidelines for Glaucoma","author":"European Glaucoma Society","year":"2008","unstructured":"European Glaucoma Society. Terminology and Guidelines for Glaucoma. 3rd ed. Savona: Editrice Dogma S.r.l; 2008.","edition":"3"},{"key":"168_CR5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1146\/annurev.neuro.051508.135728","volume":"35","author":"RW Nickells","year":"2012","unstructured":"Nickells RW, Howell GR, Soto I, John SW. Under pressure: cellular and molecular responses during glaucoma, a common neurodegeneration with axonopathy. Annu Rev Neurosci. 2012;35:153\u201379.","journal-title":"Annu Rev Neurosci"},{"key":"168_CR6","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701\u201313.","journal-title":"Arch Ophthalmol"},{"key":"168_CR7","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1517\/14656566.2014.936850","volume":"15","author":"G Hollo","year":"2014","unstructured":"Hollo G, Topouzis F, Fechtner RD. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother. 2014;15:1737\u201347.","journal-title":"Expert Opin Pharmacother"},{"key":"168_CR8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/jps.2600630304","volume":"63","author":"SS Chrai","year":"1974","unstructured":"Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci. 1974;63:333\u20138.","journal-title":"J Pharm Sci"},{"key":"168_CR9","first-page":"1","volume":"4","author":"EJ Higginbotham","year":"2010","unstructured":"Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol. 2010;4:1\u20139.","journal-title":"Clin Ophthalmol."},{"key":"168_CR10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.coph.2012.10.002","volume":"13","author":"L Mastropasqua","year":"2013","unstructured":"Mastropasqua L, Agnifili L, Mastropasqua R, Fasanella V. Conjunctival modifications induced by medical and surgical therapies in patients with glaucoma. Curr Opin Pharmacol. 2013;13:56\u201364.","journal-title":"Curr Opin Pharmacol"},{"key":"168_CR11","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1017\/S1431927614000324","volume":"20","author":"L Mastropasqua","year":"2014","unstructured":"Mastropasqua L, Agnifili L, Mastropasqua R, et al. In vivo laser scanning confocal microscopy of the ocular surface in glaucoma. Microsc Microanal. 2014;20:879\u201394.","journal-title":"Microsc Microanal"},{"key":"168_CR12","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2147\/OPTH.S46881","volume":"7","author":"JT Whitson","year":"2013","unstructured":"Whitson JT, Realini T, Nguyen QH, McMenemy MG, Goode SM. Six-month results from a phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension. Clin Ophthalmol. 2013;7:1053\u201360.","journal-title":"Clin Ophthalmol"},{"key":"168_CR13","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/archopht.121.6.835","volume":"121","author":"Y Goto","year":"2003","unstructured":"Goto Y, Ibaraki N, Miyake K. Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol. Arch Ophthalmol. 2003;121:835\u20139.","journal-title":"Arch Ophthalmol"},{"key":"168_CR14","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/01.ico.0000116526.57227.82","volume":"23","author":"RJ Noecker","year":"2004","unstructured":"Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490\u20136.","journal-title":"Cornea"},{"key":"168_CR15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/OPTH.S28104","volume":"6","author":"I Januleviciene","year":"2012","unstructured":"Januleviciene I, Derkac I, Grybauskiene L, Paulauskaite R, Gromnickaite R, Kuzmiene L. Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma. Clin Ophthalmol. 2012;6:103\u20139.","journal-title":"Clin Ophthalmol."},{"key":"168_CR16","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/bjo.86.4.418","volume":"86","author":"PJ Pisella","year":"2002","unstructured":"Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418\u201323.","journal-title":"Br J Ophthalmol"},{"key":"168_CR17","first-page":"1937","volume":"67","author":"JS Distelhorst","year":"2003","unstructured":"Distelhorst JS, Hughes GM. Open-angle glaucoma. Am Fam Physician. 2003;67:1937\u201344.","journal-title":"Am Fam Physician"},{"key":"168_CR18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/archopht.123.1.35","volume":"123","author":"SA Gandolfi","year":"2005","unstructured":"Gandolfi SA, Chetta A, Cimino L, Mora P, Sangermani C, Tardini MG. Bronchial reactivity in healthy individuals undergoing long-term topical treatment with beta-blockers. Arch Ophthalmol. 2005;123:35\u20138.","journal-title":"Arch Ophthalmol"},{"key":"168_CR19","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jamaophthalmol.2013.188","volume":"131","author":"G Katz","year":"2013","unstructured":"Katz G, Dubiner H, Samples J, Vold S, Sall K. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%. JAMA Ophthalmol. 2013;131:724\u201330.","journal-title":"JAMA Ophthalmol"},{"key":"168_CR20","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1089\/jop.2012.0235","volume":"29","author":"QH Nguyen","year":"2013","unstructured":"Nguyen QH, McMenemy MG, Realini T, Whitson JT, Goode SM. Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%\/brimonidine 0.2%. J Ocul Pharmacol Ther. 2013;29:290\u20137.","journal-title":"J Ocul Pharmacol Ther"},{"key":"168_CR21","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/eye.2013.83","volume":"27","author":"T Realini","year":"2013","unstructured":"Realini T, Nguyen QH, Katz G, Dubiner H. Fixed-combination brinzolamide 1%\/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies. Eye (Lond). 2013;27:841\u20137.","journal-title":"Eye (Lond)"},{"key":"168_CR22","doi-asserted-by":"crossref","unstructured":"Aung T, Laganovska G, Hernandez Paredes TJ, Branch JD, Tsorbatzoglou A, Goldberg I. Twice-daily brinzolamide\/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. Ophthalmology. 2014. [Epub ahead of print].","DOI":"10.1016\/j.ophtha.2014.06.022"},{"key":"168_CR23","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2165\/00002512-200825090-00002","volume":"25","author":"CA Webers","year":"2008","unstructured":"Webers CA, Beckers HJ, Nuijts RM, Schouten JS. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs Aging. 2008;25:729\u201359.","journal-title":"Drugs Aging"},{"key":"168_CR24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","volume":"29","author":"C Baudouin","year":"2010","unstructured":"Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312\u201334.","journal-title":"Prog Retin Eye Res."},{"key":"168_CR25","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1007\/s11606-007-0385-z","volume":"22","author":"WF Gellad","year":"2007","unstructured":"Gellad WF, Haas JS, Safran DG. Race\/ethnicity and nonadherence to prescription medications among seniors: results of a national study. J Gen Intern Med. 2007;22:1572\u20138.","journal-title":"J Gen Intern Med"},{"key":"168_CR26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ophtha.2005.10.034","volume":"113","author":"B Sleath","year":"2006","unstructured":"Sleath B, Robin AL, Covert D, Byrd JE, Tudor G, Svarstad B. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113:431\u20136.","journal-title":"Ophthalmology"},{"key":"168_CR27","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/ICO.0b013e3181c325b2","volume":"29","author":"RD Fechtner","year":"2010","unstructured":"Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29:618\u201321.","journal-title":"Cornea"},{"issue":"1\u20139","key":"168_CR28","first-page":"e2","volume":"153","author":"SE Skalicky","year":"2012","unstructured":"Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153(1\u20139):e2.","journal-title":"Am J Ophthalmol"},{"key":"168_CR29","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ophtha.2004.12.035","volume":"112","author":"CM Olthoff","year":"2005","unstructured":"Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112:953\u201361.","journal-title":"Ophthalmology"},{"key":"168_CR30","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0008-4182(03)80025-X","volume":"38","author":"M Houde","year":"2003","unstructured":"Houde M, Castilloux AM, Tingey D, Assalian A, LeLorier J. Prescription of topical antiglaucoma agents for patients with contraindications to beta-blockers. Can J Ophthalmol. 2003;38:469\u201375.","journal-title":"Can J Ophthalmol"},{"key":"168_CR31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2165\/00044011-200626090-00002","volume":"26","author":"S Vinker","year":"2006","unstructured":"Vinker S, Kaiserman I, Waitman DA, Blackman S, Kitai E. Prescription of ocular beta-blockers in patients with obstructive pulmonary disease: does a central electronic medical record make a difference? Clin Drug Investig. 2006;26:495\u2013500.","journal-title":"Clin Drug Investig"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-014-0168-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T21:13:49Z","timestamp":1498166029000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-014-0168-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,28]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["168"],"URL":"https:\/\/doi.org\/10.1007\/s12325-014-0168-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,28]]}}}